AGENUS INC. (NASDAQ:AGEN) Files An 8-K Results of Operations and Financial Condition

AGENUS INC. (NASDAQ:AGEN) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition.
Story continues below

On March 14, 2019, Agenus Inc. announced its financial results for the results for the quarter and year ended December 31, 2018. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated March 14, 2019

AGENUS INC Exhibit
EX-99.1 2 tv516213_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update – Gilead collaboration results in cash infusion of $150M; first milestone payment of $7.5M triggered – CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 – Next-Gen CTLA-4 advancing – expect first patient to be dosed this month – First year revenues of GSK’s SHINGRIX containing QS-21 exceed $1BnLEXINGTON,…
To view the full exhibit click here

About AGENUS INC. (NASDAQ:AGEN)

Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.

An ad to help with our costs